TrialJAMA oncology2022

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

Benjamin A Derman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.